BRPI1016232A2 - Composto de carbinol, medicamento, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doenças, e, uso do composto de carbinol - Google Patents
Composto de carbinol, medicamento, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doenças, e, uso do composto de carbinolInfo
- Publication number
- BRPI1016232A2 BRPI1016232A2 BRPI1016232A BRPI1016232A BRPI1016232A2 BR PI1016232 A2 BRPI1016232 A2 BR PI1016232A2 BR PI1016232 A BRPI1016232 A BR PI1016232A BR PI1016232 A BRPI1016232 A BR PI1016232A BR PI1016232 A2 BRPI1016232 A2 BR PI1016232A2
- Authority
- BR
- Brazil
- Prior art keywords
- shows
- carbinol compound
- optionally substituted
- drug
- pharmaceutical composition
- Prior art date
Links
- -1 CARBINOL COMPOUND Chemical class 0.000 title abstract 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 208000017520 skin disease Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
COMPOSTO DE CARBINOL, MEDICAMENTO, REGULADOR DE LXR, COMPOSIÇÃO FARMACÊUTICA, MÉTODO PARA PREVINIR E/OU TRATAR DOENÇAS, E, USO DO COMPOSTO DE CARBINOL É fornecido um agonista de LXR(Beta) inédito usado como um conservante e/ou agente terapêutico para ateroselerose; arterioselerose, tais como os que resultam de diabetes; dislipidemia; hipercolesterolemia; doenças relacionadas ao lipídeo; doenças inflamatórias que são causadas por citocinas inflamatórias; doenças de pele, tais como doenças de pele aléricas; diabetes; ou mal de Alzheimer. Ele é um composto de carbinol representado pela seguinte fórmula geral (I) ou sal do mesmo, ou seu solvato: (I) (em que, cada V e W independentemente mostra N ou C-R7; cada X e Y independentemene mostra CH2, C=O, SO2, etc; Z mostra CH ou N;; cada R1, R2 e R7 independentemente mostra um átomo de hidrogênio, grupo alquila C1-8, etc.; R3 mostra grupo alquila C1-8; R4 mostra um grupo arila C6-10 opcioalmente substituído ou um grupo heterocíclico de 5 a 11 membros opcionalmente substituído; R5 e R6 mostram um átomo de hidrogênio, etc.; L mostra um Cadeia de alquila C1-8 opcionalmente substituída por um grupo oxo, etc.; e n mostra qualquer número inteiro de 0 a 2.)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17369009P | 2009-04-29 | 2009-04-29 | |
| PCT/JP2010/003039 WO2010125811A1 (ja) | 2009-04-29 | 2010-04-28 | ヘテロ環リンカーを有するカルビノール化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1016232A2 true BRPI1016232A2 (pt) | 2023-04-11 |
Family
ID=43030853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1016232A BRPI1016232A2 (pt) | 2009-04-29 | 2010-04-28 | Composto de carbinol, medicamento, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doenças, e, uso do composto de carbinol |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8551985B2 (pt) |
| EP (1) | EP2426113B1 (pt) |
| JP (1) | JP5774984B2 (pt) |
| KR (1) | KR101671046B1 (pt) |
| CN (1) | CN102438991B (pt) |
| AU (1) | AU2010243044C1 (pt) |
| BR (1) | BRPI1016232A2 (pt) |
| CA (1) | CA2759859C (pt) |
| EA (1) | EA201171167A1 (pt) |
| IL (1) | IL215229A0 (pt) |
| MX (1) | MX2011011281A (pt) |
| NZ (1) | NZ595910A (pt) |
| TW (1) | TW201043613A (pt) |
| WO (1) | WO2010125811A1 (pt) |
| ZA (1) | ZA201107617B (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015029447A1 (ja) * | 2013-08-30 | 2015-03-05 | 興和株式会社 | 光学活性カルビノール化合物の製造方法 |
| JPWO2015037243A1 (ja) * | 2013-09-12 | 2017-03-02 | 興和株式会社 | 光学活性ヒダントイン化合物の製造方法 |
| EP3083602A1 (en) | 2013-12-20 | 2016-10-26 | Pfizer Limited | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
| CA2939120A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
| WO2017083216A1 (en) * | 2015-11-12 | 2017-05-18 | Merck Sharp & Dohme Corp. | Cyanopyridine derivatives as liver x receptor beta agonists, compositions, and their use |
| CA3010883A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
| KR102762339B1 (ko) * | 2019-01-23 | 2025-02-05 | 현대자동차주식회사 | 리튬 이차전지용 전해액, 이를 포함하는 리튬 이차전지 |
| JP7689964B2 (ja) | 2019-12-13 | 2025-06-09 | インスピルナ，インコーポレーテッド | 金属塩及びその使用 |
| CN111269134B (zh) * | 2020-04-01 | 2022-09-20 | 九江中星医药化工有限公司 | 一种苯甘氨酸及其衍生物的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6316503B1 (en) | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
| ATE283253T1 (de) | 2000-09-18 | 2004-12-15 | Glaxo Group Ltd | Substituierte aminopropoxyarylderivate als lxr agonisten |
| EP1490047B1 (en) | 2002-03-27 | 2009-12-30 | SmithKline Beecham Corporation | Certain pharmaceutically useful substituted aminoalkyl heterocycles |
| WO2004011448A1 (en) | 2002-07-25 | 2004-02-05 | Merck & Co., Inc. | Therapeutic compounds for treating dyslipidemic conditions |
| EP1407774A1 (en) | 2002-09-10 | 2004-04-14 | LION Bioscience AG | 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds |
| ATE496893T1 (de) | 2002-12-20 | 2011-02-15 | X Ceptor Therapeutics Inc | Isochinolinonderivate und deren verwendung als medikamente |
| WO2004072046A2 (en) | 2003-02-12 | 2004-08-26 | Carex S.A. | Quinoline derivatives and their use for modulation of lxr activity |
| WO2005023188A2 (en) | 2003-09-03 | 2005-03-17 | Smithkline Beecham Corporation | Compounds and methods |
| EP2284157A1 (en) | 2003-12-12 | 2011-02-16 | Wyeth | Quinolines useful in treating cardiovascular disease |
| CN1938273B (zh) | 2004-03-26 | 2011-12-14 | 霍夫曼-拉罗奇有限公司 | 四氢咔唑类及衍生物 |
| JP4620123B2 (ja) | 2004-10-01 | 2011-01-26 | エフ．ホフマン−ラ ロシュ アーゲー | ヘキサフルオロイソプロパノール置換エーテル誘導体 |
| CN101595096B (zh) * | 2006-11-30 | 2012-06-27 | 兴和株式会社 | 取代甲醇化合物 |
| TW200922582A (en) * | 2007-08-20 | 2009-06-01 | Organon Nv | N-benzyl, N'-arylcarbonylpiperazine derivatives |
| AU2009252615B2 (en) | 2008-05-29 | 2013-08-15 | Kowa Company, Ltd. | Substituted carbinol compound having cyclic linker |
-
2010
- 2010-04-28 NZ NZ595910A patent/NZ595910A/xx not_active IP Right Cessation
- 2010-04-28 US US12/769,104 patent/US8551985B2/en not_active Expired - Fee Related
- 2010-04-28 AU AU2010243044A patent/AU2010243044C1/en not_active Ceased
- 2010-04-28 CN CN201080018265.4A patent/CN102438991B/zh not_active Expired - Fee Related
- 2010-04-28 MX MX2011011281A patent/MX2011011281A/es active IP Right Grant
- 2010-04-28 TW TW099113551A patent/TW201043613A/zh unknown
- 2010-04-28 BR BRPI1016232A patent/BRPI1016232A2/pt not_active IP Right Cessation
- 2010-04-28 JP JP2011511315A patent/JP5774984B2/ja not_active Expired - Fee Related
- 2010-04-28 CA CA2759859A patent/CA2759859C/en not_active Expired - Fee Related
- 2010-04-28 KR KR1020117025163A patent/KR101671046B1/ko not_active Expired - Fee Related
- 2010-04-28 WO PCT/JP2010/003039 patent/WO2010125811A1/ja not_active Ceased
- 2010-04-28 EP EP10769511.6A patent/EP2426113B1/en active Active
- 2010-04-28 EA EA201171167A patent/EA201171167A1/ru unknown
-
2011
- 2011-09-19 IL IL215229A patent/IL215229A0/en unknown
- 2011-10-18 ZA ZA2011/07617A patent/ZA201107617B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5774984B2 (ja) | 2015-09-09 |
| CA2759859A1 (en) | 2010-11-04 |
| US20100280013A1 (en) | 2010-11-04 |
| AU2010243044C1 (en) | 2016-08-25 |
| CN102438991B (zh) | 2015-08-26 |
| AU2010243044B8 (en) | 2015-08-13 |
| TW201043613A (en) | 2010-12-16 |
| US8551985B2 (en) | 2013-10-08 |
| JPWO2010125811A1 (ja) | 2012-10-25 |
| KR20120027164A (ko) | 2012-03-21 |
| CA2759859C (en) | 2017-02-07 |
| NZ595910A (en) | 2013-06-28 |
| AU2010243044A1 (en) | 2011-11-10 |
| EA201171167A1 (ru) | 2012-06-29 |
| EP2426113A4 (en) | 2012-11-07 |
| CN102438991A (zh) | 2012-05-02 |
| WO2010125811A1 (ja) | 2010-11-04 |
| EP2426113A1 (en) | 2012-03-07 |
| AU2010243044A8 (en) | 2015-08-13 |
| MX2011011281A (es) | 2012-02-22 |
| KR101671046B1 (ko) | 2016-10-31 |
| ZA201107617B (en) | 2012-08-29 |
| AU2010243044B2 (en) | 2015-07-30 |
| EP2426113B1 (en) | 2013-11-06 |
| IL215229A0 (en) | 2011-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1016232A2 (pt) | Composto de carbinol, medicamento, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doenças, e, uso do composto de carbinol | |
| AR101177A1 (es) | Inhibidores de la syk | |
| AR086828A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| CR10250A (es) | Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| BRPI0718714B8 (pt) | arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende | |
| CR20160287A (es) | Inhibidores de syk | |
| PE20181519A1 (es) | Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido | |
| BR112015015812A2 (pt) | derivados de pirimidina fundidos a pirido ou pirrolo como inibidores de autotaxina para tratamento de dor | |
| AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR063331A1 (es) | Derivados de biaril eter urea y composiciones farmaceuticas | |
| BR122012009489B8 (pt) | processo para produzir 2-etóxi-1-{[2-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso | |
| BR122018070508B8 (pt) | derivados de arilamida triazol-substituída e seu uso | |
| PE20091819A1 (es) | DERIVADOS POLISUSTITUIDOS DE 2-HETEROARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLIACION EN TERAPEUTICA | |
| MX2010009658A (es) | Derivados de azetidina. | |
| BR112012013511A2 (pt) | derivados de difenil-pirazolopiridinas, sua preparação e seu uso como não moduladores do receptor nuclear | |
| BR112012003464B8 (pt) | compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica | |
| PE20240930A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| AR070485A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| BRPI0519287A2 (pt) | derivados de amida | |
| AR058885A1 (es) | Compuestos de piperidina 3,5-sustituidos | |
| AR087211A1 (es) | ANTAGONISTAS DE CRTh2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 11A, 12A E 13A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2728 DE 18/04/2023. |